Verona Pharma has filed an application asking the U.S. Food and Drug Administration (FDA) to approve inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The regulatory submission “is a significant milestone towards our goal of bringing this potential first-in-class therapy to COPD patients…
News
People with chronic obstructive pulmonary disease (COPD) tend to experience worsening symptoms at times when levels of pollution in their community are higher, a new U.S. study indicates. “Our findings are consistent with a growing number of studies reporting adverse effects of community-level exposure to air pollution on respiratory…
People with diabetes or prediabetes are at an increased risk of developing chronic obstructive pulmonary disease (COPD), according to a recent study conducted in the U.K. A longer period of living with diabetes or a history of smoking further increases those odds. Among people who develop COPD, those who…
Pneumagen has secured £8 million (nearly $10 million) in investments to support the clinical development of its nasal spray, called Neumifil, for the prevention and treatment of virus-induced exacerbations in people with chronic obstructive pulmonary disease (COPD). “We are very pleased to announce this funding from our existing…
Prompt treatment with Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) after a moderate or severe chronic obstructive pulmonary disease (COPD) exacerbation can lower the risk of a future worsening episodes. That’s according to data by AstraZeneca, which markets Breztri Aerosphere, in the late-breaking abstract, “Exacerbations and Real-world Outcomes…
Among people with chronic obstructive pulmonary disease (COPD) who have emphysema, individuals who continue to smoke after being diagnosed tend to have faster progression of lung damage, a recent study reported. According to researchers, these findings imply quitting smoking may help slow lung disease progression. “We were able to…
Grifols’ test kit to detect alpha-1-antitrypsin deficiency (alpha-1), called AlphaID At Home, is now available for consumers in the U.S., the company announced. The U.S. Food and Drug Administration (FDA) cleared the kit, which doesn’t require a medical prescription, last year, letting adults living in the U.S. assess…
La Mesa Rehab in San Diego — the sole comprehensive outpatient rehabilitation facility in the Southern California city — takes a holistic, innovative approach to pulmonary rehabilitation, which it emphasizes over pharmacological treatments for chronic obstructive pulmonary disease (COPD). Its COPD management strategy, of nonpharmacological therapy for pulmonary rehab,…
Primary healthcare provider VillageMD is partnering with the COPD Foundation to identify the “missing millions” thought to have chronic obstructive pulmonary disease (COPD) who remain undiagnosed and to improve access to pulmonary rehabilitation. The collaboration seeks to better identify and treat COPD at Village Medical clinics. A…
A first person with chronic obstructive pulmonary disease (COPD) has been dosed with ensifentrine, an inhaled medication in the pipeline of Verona Pharma, as part of a Phase 3 clinical trial that recently opened in China. The trial, called ENHANCE China (NCT05743075), is evaluating the efficacy…
Recent Posts
- The value of tapping into COPD community resources
- Tozorakimab reduces COPD exacerbations in two large clinical trials
- Losing myself, finding myself: How recovery is harder with COPD
- Redrawing the geography of my life one breath at a time
- A diagnosis is a map that shows our way through an unknown land